Kiro Robotics, which is now called Kiro Grifols, develops machines and equipment to automate or control key points of hospital processes, especially hospital pharmacy services, including Kiro Oncology, which automatically prepares intravenous medication for chemotherapy treatments in hospital pharmacies, minimising margins of error in the preparation of medication and the risk to healthcare professionals.
About Kiro Robotics
Kiro Robotics es una ‘spin-off’, es decir, una empresa surgida a partir de la unidad estratégica dedicara al área de salud (Mondragon Health) de la Corporación Mondragón. Creada en 2011, Kiro Robotics desarrolla máquinas y equipos que permiten automatizar o controlar puntos clave de procesos hospitalarios, en especial los servicios de farmacia hospitalaria.
Grifols purchased the company's 40% in 2014 and began direct commercialisation of Kiro Oncology in January 2016.
Grifols' entry into the company, with its healthcare experience and liquidity resources, favoured the development of its products and the possibility of international growth. Kiro currently sells its products to some of the most important hospitals in the United States, including Ann & Robert H. Lurie Children's Hospital in Chicago (a leading children's hospital) and Smilow Cancer Hospital in Yale-New Haven (one of only 45 centres with National Cancer Institute designation).
Grifols buys 40% from Kiro Robotics
With this purchase for 12.8 million euros, Grifols strengthens its hospital division by reinforcing its commitment to innovation, project continuity and internationalisation.
Grifols, which is listed on the Ibex, is one of the three leading companies in the world in the production of plasma-derived medicines and a pioneering group in research and development of therapeutic alternatives. Last year, Grifols had a turnover of 3,935 million euros.
This is not the first time that Grifols has made acquisitions in the Basque Country. In March last year, Grifols acquired 60 % of the capital of the Basque biotech company Progenika Biopharma for a total of 37 million euros.
Grifols, active in investments
Grifols has earmarked around 400 M to enter the capital of small leading companies, apart from the 5,790 million allocated to the large acquisitions of Talecris, and the diagnostic divisions of Novartis and Hologic, linked to the growth of its traditional business.
The latest investment was the purchase of GigaGen, for 35 million dollars (30.8 million euros). This company is dedicated to the discovery of new biological therapies based on the use of antibodies from immune system cells.
The acquisitions of stakes in these companies revolve around several common axes: strengthening the capacity and safety of plasma collection, providing technological innovations for the business, and investing in leading Spanish technology companies. The Catalan company makes these purchases through Grifols Innovation and New Technologies Limited, where all external R&D investments are grouped together.
Other posts that may interest you
If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.